The investigational medication of these trials, tolebrutinib, is an investigational drug. Its safety and efficacy have not been established and are being investigated in these phase III trials. Tolebrutinib has not been approved for the treatment of MS by any regulatory authority.
New Phase III Clinical Trials For Multiple Sclerosis Now Enrolling!
Once daily oral investigational medication and study-related medical care may be provided at no cost to eligible patients.